These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23839331)

  • 1. Recent advances in the treatment of homozygous familial hypercholesterolaemia.
    Marais AD; Blom DJ
    Curr Opin Lipidol; 2013 Aug; 24(4):288-94. PubMed ID: 23839331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsomal transfer protein inhibition in humans.
    Cuchel M; Rader DJ
    Curr Opin Lipidol; 2013 Jun; 24(3):246-50. PubMed ID: 23594709
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience of lomitapide therapy in patients with homozygous familial hypercholesterolaemia.
    Cuchel M; Blom DJ; Averna MR
    Atheroscler Suppl; 2014 Sep; 15(2):33-45. PubMed ID: 25257075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia.
    Gouni-Berthold I; Berthold HK
    Atheroscler Suppl; 2015 May; 18():28-34. PubMed ID: 25936301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia.
    Dixon DL; Sisson EM; Butler M; Higbea A; Muoio B; Turner B
    J Cardiovasc Nurs; 2014; 29(5):E7-E12. PubMed ID: 24231894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease.
    Stein EA; Dufour R; Gagne C; Gaudet D; East C; Donovan JM; Chin W; Tribble DL; McGowan M
    Circulation; 2012 Nov; 126(19):2283-92. PubMed ID: 23060426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of patients with familial hypercholesterolaemia.
    Reiner Ž
    Nat Rev Cardiol; 2015 Oct; 12(10):565-75. PubMed ID: 26076948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia.
    Rader DJ; Kastelein JJ
    Circulation; 2014 Mar; 129(9):1022-32. PubMed ID: 24589695
    [No Abstract]   [Full Text] [Related]  

  • 9. Familial hypercholesterolaemia.
    Nair DR; Sharifi M; Al-Rasadi K
    Curr Opin Cardiol; 2014 Jul; 29(4):381-8. PubMed ID: 24870549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe familial hypercholesterolaemia: current and future management.
    Farnier M; Bruckert E
    Arch Cardiovasc Dis; 2012 Dec; 105(12):656-65. PubMed ID: 23199621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis.
    Blom DJ; Raal FJ; Santos RD; Marais AD
    Curr Atheroscler Rep; 2019 Nov; 21(12):48. PubMed ID: 31741187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Homozygous familial hypercholesterolemia and its management.
    Marais AD; Firth JC; Blom DJ
    Semin Vasc Med; 2004 Feb; 4(1):43-50. PubMed ID: 15199432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances.
    Stefanutti C; Thompson GR
    Curr Atheroscler Rep; 2015 Jan; 17(1):465. PubMed ID: 25410046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society consensus statement.
    Bruckert E
    Atheroscler Suppl; 2014 Sep; 15(2):26-32. PubMed ID: 25257074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia.
    Perry CM
    Am J Cardiovasc Drugs; 2013 Aug; 13(4):285-96. PubMed ID: 23720215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics in the Development of Lipid Lowering Medications: Lomitapide & Mipomersen in Clinical Practice.
    Marbach JA; Thapa J; Goldenberg E; Duffy D
    Del Med J; 2015 Aug; 87(8):238-43. PubMed ID: 26402926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct adsorption of lipoproteins (DALI) from whole blood: first long-term clinical experience with a new LDL-apheresis system for the treatment of familial hypercholesterolaemia.
    Jansen M; Banyai S; Schmaldienst S; Goldammer A; Rohac M; Hörl WH; Derfler K
    Wien Klin Wochenschr; 2000 Jan; 112(2):61-9. PubMed ID: 10703153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide.
    Roeters van Lennep J; Averna M; Alonso R
    J Clin Lipidol; 2015; 9(4):607-17. PubMed ID: 26228681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iomitapide (Lojuxta). Use only in homozygous familial hypercholesterolaemia, with caution.
    Prescrire Int; 2015 Jul; 24(162):176-8. PubMed ID: 26240881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of homozygous familial hypercholesterolaemia--unmet needs, updated recommendations, and clinical experience with the MTP inhibitor, lomitapide. Concluding comments.
    Catapano AL
    Atheroscler Suppl; 2014 Sep; 15(2):52. PubMed ID: 25257077
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.